Company / Cost of Revenue
ANI Pharmaceuticals, Inc. Cost of Revenue History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$87.2M
FY2020
5-year range
-
FY2016-FY2020
Trend
+38.0%
vs FY2019
Sector context
#46 of 85
Health Care
What the data says
At $87M, ANI Pharmaceuticals, Inc.'s cost of revenue ranks #40 of 85 in the Health Care sector. Cost of Revenue returned to growth in FY2020 after 2 years of decline, reaching $87M.
Based on SEC 10-K filings.
$87M in FY2020 with a 3-year CAGR of +3.3%.
Increased from $73M to $87M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +3.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#40 of 85 in Health CareTop 46% of 85This company $87.2M Sector average $2.0B
▼
-95.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +3.3%, indicating consistent growth.
- In FY2020, cost of revenue increased 38.0% year-over-year.
- Ranks #46 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $87.2M | +38.0% |
| FY2019 | $63.2M | -13.5% |
| FY2018 | $73.0M | -7.6% |
| FY2017 | $79.0M | +62.0% |
| FY2016 | $48.8M | +389.1% |
As of FY2020 · SEC 10-K · Updated Jul 2, 2026